NASDAQ:EVOK - Evoke Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.69 -0.08 (-2.89 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$2.73
Today's Range$2.61 - $2.77
52-Week Range$1.85 - $4.09
Volume26,700 shs
Average Volume28,703 shs
Market Capitalization$45.12 million
P/E RatioN/A
Dividend YieldN/A
Evoke Pharma logoEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio4.69
Quick Ratio4.69


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book19.21


EPS (Most Recent Fiscal Year)($0.83)
Net Income$-12,220,000.00
Net MarginsN/A
Return on Equity-303.87%
Return on Assets-124.65%


Outstanding Shares16,770,000
Market Cap$45.12

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) issued its quarterly earnings data on Wednesday, May, 16th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.06. View Evoke Pharma's Earnings History.

What price target have analysts set for EVOK?

5 Wall Street analysts have issued 12-month price targets for Evoke Pharma's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Evoke Pharma's share price to reach $8.80 in the next twelve months. This suggests a possible upside of 227.1% from the stock's current price. View Analyst Ratings for Evoke Pharma.

What is the consensus analysts' recommendation for Evoke Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (6/4/2018)
  • 2. HC Wainwright analysts commented, "Ahead to Gimoti NDA Submission; Reiterate Buy Stock Data 03/08/2018 Price $2.08 Exchange NASDAQ Price Target $9.00 52-Week High $4.09 52-Week Low $1.85 Enterprise Value (M) $24.3 Market Cap (M) $32 Public Market Float (M) 12.1 Shares Outstanding (M) 15.4 3 Month Avg Volume 97,821 Short Interest (M) 1.19 Balance Sheet Metrics Cash (M) $7.7 Total Debt (M) $0.0 Total Cash/Share $0.50 Book Value/Share $0.13 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.45) (0.37) (0.14) 2Q (0.41) (0.11) (0.09) 3Q (0.29) (0.34) (0.07) 4Q (0.12) (0.02) (0.18) FY (1.15) (0.90) (0.47) 4.5 4 3.5 3 2.5 2 1.5 MAR- 17 J UL- 17 NOV- 17 MAR- 18 6 5 4 3 2 1 0 Vol. (mil) Price 2017 financial results reported. Earlier this week, Evoke Pharma reported its fourth quarter and full-year 2017 financial results. Its net loss of $0.02 per share was substantially better than our projection of a per-share net loss of $0.18." (3/6/2018)

Who are some of Evoke Pharma's key competitors?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. David A. Gonyer, Co-Founder, Chief Exec. Officer, Pres & Director (Age 54)
  • Mr. Matthew J D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 48)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 70)
  • Dr. Wayne Alves, VP of Clinical Operations

Has Evoke Pharma been receiving favorable news coverage?

News stories about EVOK stock have trended somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evoke Pharma earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $2.69.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $41.94 million. The specialty pharmaceutical company earns $-12,220,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Evoke Pharma employs 7 workers across the globe.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]

MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.